----item----
version: 1
id: {4271D208-3D47-4494-880C-9E0A94DAE175}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/22/Pfizers Rapamune 1st drug OKd for lymphangioleiomyomatosis
parent: {F5E96EB9-60E0-4AAE-863A-DF3CFDF656A2}
name: Pfizers Rapamune 1st drug OKd for lymphangioleiomyomatosis
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 2988ed94-a7c5-43f0-bf36-006801ed1a09

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 60

Pfizer's Rapamune 1st drug OK'd for lymphangioleiomyomatosis
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 58

Pfizers Rapamune 1st drug OKd for lymphangioleiomyomatosis
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1515

<p>The FDA on 28 May gave Pfizer the go-ahead to market Rapamune (sirolimus) as a treatment for lymphangioleiomyomatosis (LAM), a very rare, but progressive lung disease, which primarily affects women of childbearing age. </p><p>Rapamune is the first drug to gain approval in the US for LAM, which is characterized by an abnormal growth of smooth muscle cells that invade lung tissues, including the airways, and blood and lymph vessels, which causes destruction of the lung, resulting in airflow obstruction, ultimately limiting the delivery of oxygen to the body. </p><p>Only between two and five women per million worldwide are known to have LAM, according to the National Institute of Health's National Library of Medicine.</p><p>Rapamune already was approved for the US market as an immunosuppressive agent to help prevent organ rejection in patients 13 years or older receiving kidney transplants &ndash; gaining that nod in 1999. </p><p>But because Pfizer was able to demonstrate the drug may offer a substantial improvement over available therapies in LAM, it was deemed a breakthrough therapy by the FDA. </p><p>The drug also gained a priority review in LAM, which provided for an expedited review. </p><p>Rapamune also received orphan product designation in LAM. </p><p>Development of Rapamune in LAM was supported in part by the FDA's Orphan Products Grants Program, which provides funds for studies on safety and effectiveness of products for use in rare diseases or conditions.</p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 226

<p>The FDA on 28 May gave Pfizer the go-ahead to market Rapamune (sirolimus) as a treatment for lymphangioleiomyomatosis (LAM), a very rare, but progressive lung disease, which primarily affects women of childbearing age. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 58

Pfizers Rapamune 1st drug OKd for lymphangioleiomyomatosis
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150522T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150522T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150522T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028858
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 60

Pfizer's Rapamune 1st drug OK'd for lymphangioleiomyomatosis
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

pdfNewsLetter
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358557
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042353Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

2988ed94-a7c5-43f0-bf36-006801ed1a09
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042353Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
